科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ npj Drug Discovery.2026-05-04· Drug discovery

MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery

Yoel Shoshan, Moshiko Raboh, Michal Ozery-Flato, Vadim Ratner, Alex Golts, Jeffrey K. Weber, Ella Barkan, Simona Rabinovici-Cohen, Sagi Polaczek, Ido Amos, Ben Shapira, Liam Hazan, Matan Ninio, Sivan Ravid, Michael M. Danziger, Yosi Shamay, Sharon Kurant, Joseph A. Morrone, Parthasarathy Suryanarayanan, Michal Rosen-Zvi, Efrat Hexter

原始摘要(英文原文)· Original abstract
Modern AI (Artificial Intelligence) methods offer new opportunities in pharmacology by enabling improved modeling of disease mechanisms and drug action learned from large and heterogeneous biological datasets. A central challenge is developing models that can jointly integrate disparate biomedical modalities. We introduce MAMMAL (Molecular Aligned Multi Modal Architecture and Language), a foundation model for cross-modal learning, designed to address the challenges associated with drug discovery tasks. MAMMAL was pre-trained on 2 billion samples across protein and antibody sequences, small molecules, and gene expression profiles, and supports classification, regression, and generative tasks on cross-modal inputs. Across eleven benchmarks covering multiple stages of the drug discovery pipeline, MAMMAL achieves state-of-the-art performance on nine tasks and competitive results on two. In an antibody-antigen binding benchmark, fine-tuned MAMMAL prediction scores significantly outperform AlphaFold3 confidence scores, used here as a reference proxy for binding likelihood, in five of seven antigen targets. The MAMMAL framework and pretrained models are publicly available to support open and collaborative research.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery — 科研速览 Science Skim